{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:16:32Z","timestamp":1778242592176,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades infecciosas y microbiologia clinica (English ed.)"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.eimce.2026.503145","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:06:07Z","timestamp":1778241967000},"page":"503145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-life experience with maribavir for the treatment of cytomegalovirus infection in solid organ transplant recipients"],"prefix":"10.1016","volume":"44","author":[{"given":"Jorge","family":"Bo\u00e1n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Aizpur\u00faa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Rodr\u00edguez-Goncer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"L\u00f3pez-Medrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"San-Juan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Fern\u00e1ndez-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Aparicio-Minguij\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Manuel","family":"Caro-Teller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Andr\u00e9s","family":"Quezada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Dolores","family":"Garc\u00eda-Cos\u00edo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amado","family":"Andr\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"de Pablos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Aguado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimce.2026.503145_bib0195","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/infdis\/jiz454","article-title":"Cytomegalovirus infection in solid organ and hematopoietic cell transplantation: state of the evidence","volume":"221","author":"Haidar","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimce.2026.503145_bib0200","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1097\/00007890-199810270-00010","article-title":"Significance of cytomegalovirus for long term survival after orthotopic liver transplantation: a prospective derivation and validation cohort analysis","volume":"66","author":"Falagas","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.eimce.2026.503145_bib0205","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1086\/591532","article-title":"Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation","volume":"47","author":"San Juan","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimce.2026.503145_bib0210","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.eimce.2026.503145_bib0215","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/cid\/cix259","article-title":"Risk factors and outcomes of ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients","volume":"65","author":"Fisher","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimce.2026.503145_bib0220","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41409-018-0257-7","article-title":"Clinical and genotypic CMV drug resistance in HSCT recipients: a single center epidemiological and clinical data","volume":"54","author":"Vejrazkova","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.eimce.2026.503145_bib0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2015.06.009","article-title":"Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease and non-relapse mortality","volume":"21","author":"Liu","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.eimce.2026.503145_bib0230","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/jac\/dkq368","article-title":"Drug-resistant cytomegalovirus in transplant recipients: a French cohort study","volume":"65","author":"Hantz","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimce.2026.503145_bib0235","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1399-0012.2007.00761.x","article-title":"Emergence of drug resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes","volume":"22","author":"Eid","year":"2008","journal-title":"Clin Transplant"},{"key":"10.1016\/j.eimce.2026.503145_bib0240","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1086\/338143","article-title":"High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy","volume":"185","author":"Limaye","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimce.2026.503145_bib0245","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12852","article-title":"Safety and efficacy of foscarnet for the management of ganciclovir-resistant or refractory cytomegalovirus infections: a single-center study","volume":"20","author":"Pierce","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.eimce.2026.503145_bib0250","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jinf.2014.07.001","article-title":"Clinical impact of neutropenia related with the preemptive therapy of CMV infection in solid organ transplant recipients","volume":"69","author":"Mart\u00edn-Gandul","year":"2014","journal-title":"J Infect"},{"key":"10.1016\/j.eimce.2026.503145_bib0255","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1182\/blood.V90.6.2502","article-title":"Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome","volume":"90","author":"Salzberger","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.eimce.2026.503145_bib0260","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1128\/JVI.77.2.905-914.2003","article-title":"The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress","volume":"77","author":"Krosky","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.eimce.2026.503145_bib0265","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/rmv.615","article-title":"Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir","volume":"19","author":"Prichard","year":"2009","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.eimce.2026.503145_bib0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000275","article-title":"Viral mimicry of Cdc2\/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress","volume":"5","author":"Hamirally","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.eimce.2026.503145_bib0275","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jcv.2006.07.010","article-title":"Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet","volume":"37","author":"Drew","year":"2006","journal-title":"J Clin Virol"},{"key":"10.1016\/j.eimce.2026.503145_bib0280","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1182\/blood-2007-11-121558","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study","volume":"111","author":"Winston","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.eimce.2026.503145_bib0285","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial","volume":"75","author":"Avery","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimce.2026.503145_bib0290","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/cid\/ciad709","article-title":"Treatment for first cytomegalovirus infection post-hematopoietic cell transplant in the AURORA trial: a multicenter, double-blind, randomized phase 3 trial comparing maribavir with valganciclovir","volume":"78","author":"Papanicolaou","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimce.2026.503145_bib0295","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1016\/j.transproceed.2018.08.009","article-title":"Risk factors for the development of cytomegalovirus resistance in solid organ transplantation: a retrospective case\u2013control study","volume":"50","author":"Sandkovsky","year":"2018","journal-title":"Transplant Proc"},{"key":"10.1016\/j.eimce.2026.503145_bib0300","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1097\/TP.0000000000004855","article-title":"What's new: updates on cytomegalovirus in solid organ transplantation","volume":"108","author":"Stewart","year":"2024","journal-title":"Transplantation"},{"key":"10.1016\/j.eimce.2026.503145_bib0305","doi-asserted-by":"crossref","DOI":"10.1177\/13596535231195431","article-title":"Retrospective chart review of transplant recipients with cytomegalovirus infection who received maribavir in the phase 3 SOLSTICE trial: data at 52 weeks post-maribavir treatment initiation","volume":"28","author":"Bassel","year":"2023","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimce.2026.503145_bib0310","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14444","article-title":"Real-world experience with maribavir for treatment of refractory or resistant cytomegalovirus infection in hematopoietic cell transplant recipients and hematologic malignancy patients","volume":"27","author":"Daher","year":"2025","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.eimce.2026.503145_bib0315","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14427","article-title":"Successful management of refractory cytomegalovirus infection after intestinal transplantation using maribavir","volume":"27","author":"Liu","year":"2025","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.eimce.2026.503145_bib0320","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14275","article-title":"Maribavir failure in refractory cytomegalovirus infection in a lung transplant patient on extracorporeal membrane oxygenation","volume":"26","author":"Kroll","year":"2024","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.eimce.2026.503145_bib0325","article-title":"Maribavir for treatment of cytomegalovirus infection in a liver-transplanted patient","volume":"186","author":"Loft","year":"2024","journal-title":"Ugeskr Laeger"},{"key":"10.1016\/j.eimce.2026.503145_bib0330","article-title":"Determinants of virological outcomes in kidney transplant recipients treated with maribavir for refractory cytomegalovirus infection","author":"Kasriel","year":"2025","journal-title":"Am J Transplant"},{"key":"10.1016\/j.eimce.2026.503145_bib0335","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/cid\/ciy696","article-title":"Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials","volume":"68","author":"Chemaly","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimce.2026.503145_bib0340","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/cid\/ciae321","article-title":"Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from the transplant associated virus infections forum","volume":"79","author":"Ljungman","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimce.2026.503145_bib0345","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1399-3062.2006.00199.x","article-title":"Ex vivo monitoring of human cytomegalovirus-specific CD8+T-cell responses using QuantiFERON-CMV","volume":"9","author":"Walker","year":"2007","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.eimce.2026.503145_bib0350","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1097\/TP.0000000000005374","article-title":"The fourth international consensus guidelines on the management of cytomegalovirus in solid organ transplantation","volume":"109","author":"Kotton","year":"2025","journal-title":"Transplantation"},{"key":"10.1016\/j.eimce.2026.503145_bib0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.trre.2024.100875","article-title":"Management of cytomegalovirus in adult solid organ transplant patients: GESITRA-IC-SEIMC, CIBERINFEC, and SET recommendations update","volume":"38","author":"Ruiz-Arabi","year":"2024","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.eimce.2026.503145_bib0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104616","article-title":"Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","volume":"172","author":"Chou","year":"2019","journal-title":"Antiviral Res"},{"key":"10.1016\/j.eimce.2026.503145_bib0365","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimce.2026.503145_bib0370","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s10928-024-09939-2","article-title":"Population pharmacokinetics and exposure\u2013response relationships of maribavir in transplant recipients with cytomegalovirus infection","volume":"51","author":"Song","year":"2024","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.eimce.2026.503145_bib0375","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1128\/AAC.46.9.2969-2976.2002","article-title":"Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding","volume":"46","author":"Lalezari","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimce.2026.503145_bib0380","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0321180","article-title":"Optimizing CMV therapy: population pharmacokinetics and Monte Carlo simulations for letermovir and maribavir dosage","volume":"20","author":"Fromage","year":"2025","journal-title":"PLoS One"}],"container-title":["Enfermedades infecciosas y microbiologia clinica (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2529993X26000754?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2529993X26000754?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:06:59Z","timestamp":1778242019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2529993X26000754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2529993X26000754"],"URL":"https:\/\/doi.org\/10.1016\/j.eimce.2026.503145","relation":{},"ISSN":["2529-993X"],"issn-type":[{"value":"2529-993X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-life experience with maribavir for the treatment of cytomegalovirus infection in solid organ transplant recipients","name":"articletitle","label":"Article Title"},{"value":"Enfermedades infecciosas y microbiologia clinica (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimce.2026.503145","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"503145"}}